Leerink Partners has downgraded Acadia Healthcare Company Inc (ACHC) to Market Perform from Outperform as of December 2, 2025. The current share price stands at $14.55.
This downgrade suggests increased caution regarding Acadia's outlook, potentially reflecting concerns about competitive pressures, market conditions, or execution risks that may affect the company's performance. Acadia Healthcare provides behavioural healthcare services across the United States and operates a network of 262 facilities with over 11,850 beds in 39 states and Puerto Rico. The company reported a market capitalisation of $1.4 billion and has a trailing price-to-earnings ratio of 13.04, with an earnings per share of 1.18.
Upcoming earnings are scheduled for August 3, 2026, with an estimated EPS of $0.75 and revenue of $905.1 million. Recent earnings performance has shown mixed results, with Q3 2025 reporting an EPS of $0.72, surpassing estimates by 5.2%. Analysts currently maintain a consensus rating of Buy, with 5 Strong Buy, 9 Buy, and 6 Hold ratings.
Analyst ratings and price targets serve as professional opinions based on research and financial models. While these assessments can provide useful insights, they are based on assumptions and estimates that may not materialise as expected. Investment decisions should consider various factors, including company fundamentals and industry trends, rather than relying solely on analyst views.